Nuerocrine Biosciences About
Nuerocrine Biosciences Neurocrine Biosciences, Inc. is a product-based
biopharmaceutical company focused on neurological and endocrine-related diseases
and disorders. Our product candidates address some of the largest pharmaceutical
markets in the world including insomnia,
anxiety,
depression,
various female and male health disorders, multiple
sclerosis, diabetes,
irritable bowel syndrome, eating disorders, pain,
and autoimmunity
disorders. Neurocrine currently has 17 programs in various stages of
research and development. Six of these programs have been advanced into
clinical trials. Our lead clinical development program, indiplon,
for the treatment of
insomnia, partnered with Pfizer, has had two New Drug Applications
filed with the Food and Drug Administration (FDA). We have successfully
completed three Phase I single and multiple dose trials with GnRH (Gonadotropin-releasing
Hormone) for the treatment of women's health disorders. The Company has
two Altered Peptide Ligand (APL) products in Phase II clinical development,
NBI-5788 for multiple
sclerosis,
and NBI-6024 for Type
I Diabetes. Neurocrine initiated a Phase I clinical trial with
its proprietary compound, urocortin 2 in healthy volunteers to expects
to initiate a Phase II clinical study in patients with mild to moderate congestive
heart disease in early 2005. Clinical
Trial Data for Neurocrine Biosciences
Indiplon-- Insomnia -- -- action by enhancing the action of the
inhibitory neurotransmitter GABA CRF R Antagonist -- Anxiety and
depression NBL- 5788-- Multiple Sclerosis Urocortin 2 --
Acute congestive
heart failure (CHF) GnRH Antagonist -- Endometriosis